IVD (in vitro diagnostic) tools have risen as a new trend in the diagnostic industry and has been broadly used for the diagnosis of diseases, for monitoring drug therapies, and for determining prognosis. Now, Creative Biolabs offers a comprehensive series of IVD antibody development services targeting novel biomarkers of colorectal cancer. Our technical experts and scientists specialized in IVD are pleased to assist in the development of highly specific IVD antibodies for CD166.
CD166 (cluster of differentiation 166), also known as activated leukocyte cell adhesion molecule (ALCAM) or CD6 ligand (CD6L), is a 100-105 kD type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily of proteins. It is an activated leukocyte cell adhesion molecule that binds to cell surfaces through CD6. CD166 has been detectable in activated T cells, activated monocytes, epithelial cells, bone marrow cells, neurons, fibroblasts, lymphoid cells, hepatocytes, melanoma cells, and also in sebaceous and sweat glands. CD166 plays a vital role in mediating adhesion interactions between thymic epithelial cells and CD6+ cells in the process of intrathymic T cell development. In recent years, CD166 has also been used as a potential cancer stem cell marker.
Colorectal cancer (CRC) is the third most common cause of death from cancer in both sexes worldwide, with a high incidence that remained stable over the past decades. Although this disease is surgically curable in the early stages, the tumor is frequently not symptomatic until the metastatic stage, which is related to high mortality. Accordingly, there is an increasing need to develop more effective diagnosis and prevention strategies for CRC and to enhance our ability to predict the disease’s course. In a previous investigation, CD166 is shown to be frequently upregulated in colorectal cancer and significantly shorter survival time has been found in patients whose tumors exhibited membranous ALCAM expression. Thus, CD166 can be regarded as a new independent prognostic marker, which emphasizes the significance of CD166 in the progression of this cancer.
Fig.1 CD166 expression in human pancreatic tissues.1
Since the overexpression of CD166 in the neoplastic colonic epithelia of adenomas and carcinomas has been found, CD166 expression can be regarded as a new prognostic marker in colon cancer. Creative Biolabs currently offers the most comprehensive CD166 antibody development services of the diagnostic level, which can be used for the development of diagnostic kits to aid the diagnosis and prognosis of cholangiocarcinoma. Our services are flexible and can be customized to meet the special requirements of our clients.
Creative Biolabs is a long-term expert that has concentrated on the research and development of antibody realm for over decades and successfully contributed a range of services specifically tailored to antibody development. We are confident in applying our experience, industry, and regulatory knowledge to design actual strategic packages pertinent to customers’ project. Contact us to get more information.
Reference
For Research Use Only.
